Oncology

Approximately 80% of manufacturers are already managing their products, many of which are oncology drugs, through a limited distribution model.

The discovery may pave the way for the development of personalized medicine in order to target this newly discovered form of the disease.

Enzalutamide (Xtandi) is the first and only FDA-approved oral medication for both non-metastatic and metastatic castration-resistant prostate cancer.

With this new indication, enzalutamide is the first and only FDA-approved oral medication for both non-metastatic and metastatic CRPC.

A look at last week's top stories in the world of pharmacy.

Nivolumab (Opdivo) plus ipilimumab (Yervoy) approved for patients with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Hepatocellular carcinoma is the most common type of liver cancer in adults.

Approvals and indications of this drug were based on 3 main clinical trials.

New research identified predictors of long-term survival and health-related quality of life in patients with newly diagnosed multiple myeloma.

The PALOMA-3 trial evaluated palbociclib (Ibrance) in combination with fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.

Researchers have developed a laser-sonic scanner with the ability to detect tumors in as little as 15 seconds.

Using a DNA test to identify genetic variants in men that increase the likelihood of prostate cancer may help guide interventions for those at high risk and improve disease prevention.

Top news of the day from across the health care landscape.

Using real-time symptom reports, a well-trained classification algorithm can detect lymphedema more accurately than current clinical methods.

Atezolizumab (Tecentriq, Roche) plus chemotherapy nab-paclitaxel (Abraxane) met its co-primary endpoint of progression-free survival in patients with metastatic triple-negative breast cancer.

Atezolizumab (Tecentriq) plus chemotherapy nab-paclitaxel (Abraxane) significantly reduced the risk of disease worsening or death in patients with metastatic triple-negative breast cancer.

Encorafenib (Braftovi) and binimetinib (Mektovi) is now available for patients with advanced BRAF-mutant melanoma.

Researchers identified a trend in which higher body mass index was associated with lower breast cancer risk in women before menopause.

A Connecticut health system was able to transform the way it manages oral oncology services to improve patient outcomes and experiences.

The oncology treatment landscape is currently in the midst of an extraordinary evolution, with significant progress achieved in the development of both targeted and immunooncology treatments.

Nivolumab plus low-dose ipilimumab demonstrated positive initial results in part 1 of a phase 3 study.

Following results of decreased survival associated with the use of these medications as a single therapy, the FDA is restricting use in some patients with urothelial cancer.

Officials with the FDA have approved bevacizumab (Avastin, Genentech) in combination with carboplatin and paclitaxel for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The study aimed to analyze whether age, gender, socioeconomic factors, comorbidity, and medication may affect the risk of lung cancer in patients with COPD.

Although precision medicine holds promise for advanced cancer care, many oncologists indicated challenges in the adoption of new, targeted therapies.

Data revealed at ASCO shows combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel reduced the risk of death by 22% compared with bevacizumab and chemotherapy.

In a study presented at ASCO, Cemiplimab shows substantial activity and durable responses with an acceptable safety profile in treatment of metastatic cutaneous squamous cell carcinoma.

Rituximab (Rituxan) and lenalidomide (Revlimid) showed similar efficacy to rituximab plus chemotherapy, according to findings presented at the 2018 ASCO Annual Meeting.